QT Imaging Holdings (QTI) investor relations material

Strategic vision and technology evolution

• Mission focuses on transforming breast health with safe, high-resolution, cost-effective imaging solutions, targeting gaps in current technologies.

• Platform integrates proprietary hardware, advanced image reconstruction, cloud infrastructure, and plans for AI-enabled clinical applications.

• Designed to improve patient experience, provide objective data for clinicians, and deliver value across a growing installed base.

• Addresses limitations of mammography, MRI, and ultrasound by offering a single-step, operator-independent, 3D imaging process without radiation or compression.

• FDA-cleared, patent-protected Breast Acoustic CT scanner delivers MRI-like performance in a patient-friendly, scalable format.

Market opportunity and clinical adoption

• Estimated total addressable market of $2.5B in 2026, growing to $3.8B by 2030, with reimbursed segments rising accordingly.

• Regulatory tailwinds include FDA recognition of breast density and new CPT code X579T effective January 2027.

• Clinical studies at Mayo Clinic and Cyber Cancer Centre support diagnostic performance and treatment response monitoring.

• Over 12,000 women imaged, building real-world evidence for broader adoption.

• Regulatory approvals secured in Saudi Arabia, UAE, and Israel, with CE mark targeted for Q2 2027.

Business model and commercial execution

• Revenue model starts with hardware and expands to recurring cloud software and future AI diagnostic layers.

• Transitioning from distributor-led to hybrid sales model to increase margin and customer control.

• Revenue grew from $4.9M in 2024 to $18.9M in 2025, with $14M in the first half of 2026 and 28 scanners shipped.

• 2026 revenue guidance affirmed at $39M, more than doubling 2025 revenue.

• Revenue per scanner and gross margins are increasing, with estimated $488K per scanner and ~45% gross margin in 2026.